Fat necrosis is a benign but real concern
Consortium aims to reduce life-threatening side effect of therapy
Predicts drug response in patient with rare, aggressive cancer
Outcomes hold promise for future RCT results
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Impact on tumor immune microenvironment and response to immunotherapy
Encouraging results for an incurable bone cancer
Does tumor location matter?
An IL-15 superagonist shows promise
Men with the HSD3B1(1245C) variant metabolize abiraterone differently
Tc9 cells have less intracellular cholesterol than other T cells
Advertisement
Advertisement